Biotech Values

[Bickema]

RVNC - I listened to the call.

Management is so mum on Daxi approval to the point that if I had to guess I'd say the manufacturing facility has not yet been inspected.

That being said the derma line is impressive and hintMD is a data collecting machine.

It may take a little time but Revance is building a next generation healthcare powerhouse.

I think a lot of investors fail to grasp the high barrier for entry into this market and the tailwinds that Revance will ride once Daxi is approved.

The aesthetic toxin's market is expanding in every direction like a sphere growing bigger.

1. Increasing overall adoption and acceptance of toxins
2. Increasing overall aging population
3. Patients using toxins are getting younger and younger
4. More and more men are using toxins
5. Social media and vanity tailwinds


This list goes on and on. I can't remember who said it but I believe it was Dan Browne who said something along the lines of how he doesn't believe there will be another approved toxin after Daxi due to the high barrier for entry.